论文部分内容阅读
目的:研究PPAR-γ增殖物激动剂(罗格列酮)对ANP及合并肺损伤大鼠是否有保护作用。方法:50只健康雄性SD大鼠随机分为5组,正常对照组、假手术组、ANP组、罗格列酮预防组,罗格列酮治疗组。正常对照组,未做任何处理;假手术组,腹腔内注射同等剂量生理盐水;采用大剂量精氨酸腹腔注射诱导ANP模型,预防组于造模前60min给予罗格列酮10mg/kg,2次,每次间隔30min,治疗组于造模后60min给予罗格列酮10mg/kg,2次,每次间隔30min。各组于造模后24h处死大鼠,观察大鼠血清AMY、TNF-α和IL-1β水平变化,同时检测胰腺和肺的组织病理变化和肺组织髓过氧化物酶(MPO)的变化。结果:ANP组AMY、TNF-α、IL-1β和MPO均较对照组和假手术组明显升高(P<0.001);罗格列酮预防和治疗组血清AMY、TNF-α、IL-1β、肺组织中MPO水平较ANP组明显下降,且胰腺和肺的病理损伤也明显减轻(P<0.001)。结论:罗格列酮能明显降低ANP的炎症,能明显减少TNF-α、IL-1β的产生,能降低肺组织中MPO含量,对ANP及合并的肺损伤具有保护和治疗作用。
AIM: To investigate whether PPAR-γ proliferative agonist (rosiglitazone) has a protective effect on ANP and lung injury in rats. Methods: Fifty healthy male SD rats were randomly divided into 5 groups: normal control group, sham operation group, ANP group, rosiglitazone prevention group and rosiglitazone treatment group. Normal control group, without any treatment; sham operation group, intraperitoneal injection of the same dose of saline; high dose of arginine induced by intraperitoneal injection of ANP model, prevention group 60min before modeling given rosiglitazone 10mg / kg, 2 Times, each interval of 30min, the treatment group given rosiglitazone 10mg / kg 60min after modeling, 2 times, each interval of 30min. The rats in each group were sacrificed 24 h after modeling to observe the changes of serum AMY, TNF-α and IL-1β levels, and to detect the histopathological changes of the pancreas and lungs and the changes of lung tissue myeloperoxidase (MPO). Results: The levels of AMY, TNF-α, IL-1β and MPO in ANP group were significantly higher than those in control group and sham operation group (P <0.001) , The level of MPO in lung tissue was significantly lower than that in ANP group, and the pathological damage of pancreas and lung was also significantly reduced (P <0.001). CONCLUSION: Rosiglitazone can significantly reduce the inflammation of ANP, and can significantly reduce the production of TNF-α and IL-1β, reduce the content of MPO in lung tissue and protect and treat ANP and lung injury.